Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

Cancer Clinical Trial

Official title:

A Phase I, Open-Label, Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide (Xtandi) or Abiraterone (Zytiga) in Male Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02380313
• Other study ID #: 201672
• Status: Withdrawn
• Phase: Phase 1
• First received: March 2, 2015
• Last updated: October 5, 2016
• Start date: October 2015
• Est. completion date: May 2017

Study information

• Verified date: October 2016
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is being conducted to characterize the safety and recommended phase 2 dose (RP2D) of combining afuresertib, independently with 2 approved drugs: enzalutamide (Xtandi®, "Xtandi is a trademark of Astellas Pharma, Inc." ) and abiraterone (Zygita®, "Zytiga is a trademark of Janssen Biotech, Inc."). The study will be conducted in two parts. Part 1, a dose escalation phase, will establish RP2D of afuresertib when administered with enzalutamide or abiraterone. Part 2, a dose expansion phase, will further evaluate long-term safety of the combinations at the RP2Ds in additional subjects. Dose-finding cohorts will be studied in parallel and will evaluate safety and pharmacokinetic to guide selection of the dose regimens for further evaluation. Part 2 will begin once the RP2Ds have been established in Part 1. Additional doses and/or schedules may be explored if warranted, based upon the pharmacokinetic (PK) and pharmacodynamic (PD) assessments or emerging preclinical evidence. Overall, approximately 60 chemotherapy-naïve subjects with mCRPC and who are receiving either enzalutamide or abiraterone will be enrolled into the study.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed written informed consent provided

• Males >=18 years of age (at the time consent is obtained)

• Histologically or cytologically confirmed diagnosis of metastatic prostate adenocarcinoma, without neuroendocrine or small cell features

• Surgically or medically castrated, with testosterone levels of <=50 nanogram (ng)/deciliter (dL) (<=1.73 nanomolar [nM]). If the subject is being treated with luteinizing hormone releasing hormone analogs (subjects who have not undergone orchiectomy), this therapy must have been initiated at least 4 weeks prior to Cycle 1 Day 1 and must be continued throughout the study.

• Rising Prostate-specific antigen (PSA) after initial response to enzalutamide or abiraterone without radiographic or symptomatic evidence of progression (per Prostate Cancer Working Group 2 criteria): Most recent enzalutamide dose received is 160 milligram (mg) once daily with no change in dose for at least 4 weeks prior to Cycle 1, Day 1. Most recent abiraterone dose received is 1000 mg once daily with prednisone 5 mg twice daily (BID), with no change in dose for at least 2 weeks prior to Cycle 1, Day 1.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Able to swallow and retain orally administered medication.

• Adequate baseline organ function defined as: Absolute neutrophils count>=1.5 x 10^9/Liter (L), hemoglobin>=9 grams (g)/dL, Platelets>=75 x 10^9/L, Prothrombin time/International normalized ratio<=1.3 x Upper limit of normal (ULN), Partial thromboplastin time<=1.3 x ULN, Albumin>=2.5 g/dL, Total bilirubin<=1.5 ULN, Aspartate aminotranseferase and Alanine aminotransferase <=2.5 x ULN, Serum creatinine<=ULN OR Estimated glomerular filtration rate>=30 millilite per Minute (mL/min), Fasting Serum Glucose <126 mg/dL, Hemoglobin A1C<=8%. Note: Subjects with ALT or bilirubin values outside the ranges noted in the table above due to Gilbert's syndrome or asymptomatic gallstones are not excluded.

• Male subject with a female partner of childbearing potential must either have a prior vasectomy or agree to use effective contraception from time of first dose of study treatment until 3 months after last dose of study treatment.

Exclusion Criteria:

• Prior treatment with cytotoxic chemotherapy or inhibitors of the Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/ mechanistic target of rapamycin (mTOR) pathway.

• Any investigational drug(s) within 30 days or 5 half-lives of enrollment, whichever is longer.

• Prior malignancy other than Castrate-resistant prostate cancer (CRPC). Exception:

Subjects who have been disease-free of the prior malignancy for 3 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.

• Any unresolved >=Grade 2 (per Common Toxicity Criteria for Adverse Events 4.0) toxicity from previous anti-cancer therapy at the time of enrollment, except alopecia or Grade 2 anemia (if hemoglobin is >9.0 gram (g)/dL).

• Presence of any clinically significant gastrointestinal (GI) abnormality or other condition(s) that may alter absorption such as malabsorption syndrome or major resection of the stomach or substantial portion of the small intestine. NOTE: If clarification is needed as to whether a GI abnormality, condition or resection will significantly affect the absorption of study treatment, contact the Sponsor's Medical Monitor.

• Major surgery, radiation therapy, or immunotherapy within 28 days prior to enrollment.

• Known active infection requiring intravenous (IV) or oral anti-infective treatment.

• Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal or cardiac disease).

• For those subjects who will receive afuresertib plus enzalutamide: History of seizures, underlying brain injury with loss of consciousness, transient ischemic attack in the past 12 months, cerebral vascular accident, brain metastases, brain arteriovenous malformation, or use of concomitant medications that may lower the subjects' seizure threshold.

• History or evidence of cardiovascular risk including any of the following:

Clinically significant ECG abnormalities including second degree (Type II) or third degree atrioventricular block.

History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, stenting, or bypass grafting within the past 6 months prior to enrollment.

Class III or IV heart failure as defined by the New York Heart Association functional classification system Left ventricular ejection fraction (LVEF) below 50% Known cardiac metastases Corrected QT interval of >470 millisecond (msec) (or >480 msec with bundle branch block)

• Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to afuresertib, enzalutamide, abiraterone, or excipients.

• Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures.

• Have a known Human Immunodeficiency Virus (HIV) infection.

• Subjects who are Hepatitis B surface antigen (HbSAg) positive.

• Subjects with a positive test for Hepatitis C virus (HCV) antibody, regardless of viral load. (Note: the subject is eligible if a confirmatory recombinant immunoblot assay [RIBA] test is negative).

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cancer

Intervention

Drug:
• Afuresertib
White of off-white round immediate release tablet for oral administration with unit dose strength of 50 mg and 75 mg to achieve the dosage level of 100 mg, 125 mg, 150 mg or 200 mg once daily.
• Enzalutamide
Opaque white to off-white capsule for oral administration with unit dose strength of 40mg to achieve dose level of 160 mg once daily.
• Abiraterone
White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.
• Prednisone
Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events (AEs), serious adverse events (SAEs) and dose limiting toxicities as a safety measure.	All AEs and SAEs will be collected and recorded from receipt of first dose of study drug until 30 days after the last dose of study drug, or until the start of subsequent therapy.	From first dose of study drug until 30 days after last dose of study drug (assessed up to average of 6 months).	No
Primary	Change from baseline in composite of laboratory parameters as a safety measure: hematology, clinical chemistry and urinalysis.	Changes in the laboratory parameter including hematology, clinical chemistry and urinalysis will be assessed as a measure of safety tolerability and to establish RP2D.	From baseline up to end of treatment (assessed up to average of 6 months).	No
Primary	Change from baseline in electrocardiogram values as a safety measure.	Changes in electrocardiograms (ECGs) values will be assessed as a measure of safety, tolerability and to establish RP2D.	From baseline up to average of 6 months.	No
Primary	Change from baseline in composite of vital signs as a safety measure: blood pressure, temperature and pulse rate.	Changes in vital sign values of blood pressure, temperature and pulse rate will be assessed as a measure of safety, tolerability and to establish RP2D.	From baseline up to end of treatment (assessed up to average of 6 months).	No
Primary	Composite of PK parameters as a measure of RP2D following administration of afuresertib plus enzalutamide or afuresertib plus abiraterone: AUC and Cmax.	PK parameters of area under time concentration curve (AUC) and maximum plasma concentration (Cmax) will be evaluated to determine RP2D of afuresertib.	Pre-dose Sample on Day 1 of Cycle 1, 2, 3, 4, and then every 12 weeks and again on Day 1 of Cycle 7 (assessed up to 169 days).	No
Primary	Composite of PK parameters as a measure of RP2D following administration of afuresertib plus abiraterone: AUC and Cmax.	PK parameters of area under time concentration curve (AUC) and maximum plasma concentration (Cmax) will be evaluated.	Pre-dose and 2 hours post dose sample will be collected on Day 8 of Cycle 1.	No
Primary	Number of participants with adverse events, serious adverse events and dose limiting toxicities to establish RP2D of afuresertib.	All AEs and SAEs will be collected and recorded from receipt of first dose of study drug until 30 days after the last dose of study drug, or until the start of subsequent therapy.	Cycle 1 (28 days).	No
Primary	Change from baseline in composite of laboratory parameters to establish RP2D of afuresertib: hematology, clinical chemistry and urinalysis.	Changes in the laboratory parameter including hematology, clinical chemistry and urinalysis will be assessed as a measure of safety tolerability and to establish RP2D.	From baseline up to 28 days (Cycle 1).	No
Primary	Change from baseline in electrocardiogram values to establish RP2D of afuresertib.	Changes in electrocardiograms (ECGs) will be assessed as a measure of safety, tolerability and to establish RP2D.	From baseline up to 28 days (Cycle 1).	No
Primary	Change from baseline composite of vital sign values to establish RP2D of afuresertib: blood pressure, temperature and pulse rate.	Changes in vital sign values of blood pressure, temperature and pulse rate will be assessed as a measure of safety, tolerability and to establish RP2D.	From baseline up to 28 days (Cycle 1).	No
Secondary	Composite of afuresertib PK parameters following administration with enzalutamide: AUC and Cmax.	PK profile of afuresertib will be established following administration with enzalutamide by assessing AUC and Cmax.	Blood samples will be collected at pre-dose, 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post dose on Day 1of Cycle 1.	No
Secondary	Composite of enzalutamide PK parameters following administration alone and in combination with afuresertib: AUC and Cmax.	PK profile of enzalutamide will be establish by assessing AUC and Cmax when administered alone and in combination with afuresertib.	Blood samples will be collected at pre-dose, 0.5, 1, 2, 3, 4, 6 and 24 hours post dose on Day-1 and Day 1 in Cycle 2.	No
Secondary	Composite of PK parameters following administration afuresertib and abiraterone alone and in combination with each other: AUC and Cmax.	PK profile of afuresertib and abiraterone will be establish by assessing AUC and Cmax when administered alone and in combination with each other.	Blood samples will be collected at pre-dose, 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post dose on Day 15 of Cycle 1 and Day 1 of Cycle 2 for afuresertib and on Day-1 and Day 1 in Cycle 2 for abiraterone.	No